Research programme: osteoporosis therapeutics - Zealand PharmaAlternative Names: ZP 2307
Latest Information Update: 11 May 2008
At a glance
- Originator Zealand Pharma
- Class Peptides
- Mechanism of Action Gap junction modulators; Parathyroid hormone receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Osteoporosis
Most Recent Events
- 09 May 2008 Preclinical development is ongoing
- 11 May 2004 Preclinical trials in Osteoporosis in Denmark (unspecified route)